Fellow of the European Confederation of Medical Mycology (ECMM)
Oliver A. Cornely spends much of his time researching Internal medicine, Surgery, Voriconazole, Neutropenia and Posaconazole. He has included themes like Amphotericin B, Gastroenterology, Fluconazole, Mycosis and Aspergillosis in his Internal medicine study. His Surgery research includes elements of Clostridium difficile, Vancomycin, Fidaxomicin and Adverse effect.
His research in Voriconazole tackles topics such as Hematopoietic stem cell transplantation which are related to areas like Cumulative incidence. His Neutropenia study combines topics from a wide range of disciplines, such as Immunology, Pharmacokinetics and Leukopenia. In his research, Zygomycosis is intimately related to Mucormycosis, which falls under the overarching field of Posaconazole.
Oliver A. Cornely mainly investigates Internal medicine, Intensive care medicine, Aspergillosis, Surgery and Posaconazole. His biological study deals with issues like Voriconazole, which deal with fields such as Amphotericin B. His research investigates the connection with Intensive care medicine and areas like Hematology which intersect with concerns in Cancer.
Oliver A. Cornely combines subjects such as Aspergillus fumigatus, Bronchoalveolar lavage, Polymerase chain reaction and Aspergillus with his study of Aspergillosis. His studies in Surgery integrate themes in fields like Adverse effect and Incidence. His biological study spans a wide range of topics, including Mucormycosis and Pharmacokinetics, Pharmacology.
His primary scientific interests are in Internal medicine, Aspergillosis, Intensive care medicine, Voriconazole and Epidemiology. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Amphotericin B. His Aspergillosis research incorporates themes from Azole, Multicenter study, Aspergillus, Hematological malignancy and Bronchoalveolar lavage.
His work deals with themes such as Pulmonary aspergillosis, Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019 and MEDLINE, which intersect with Intensive care medicine. His study in Voriconazole is interdisciplinary in nature, drawing from both Clinical research and Lung. In his research on the topic of Epidemiology, Mucormycosis and Pediatrics is strongly related with Mortality rate.
His main research concerns Internal medicine, Voriconazole, Intensive care medicine, Aspergillosis and Coronavirus disease 2019. The Internal medicine study combines topics in areas such as Mucormycosis and Amphotericin B. His research in Amphotericin B intersects with topics in Fluconazole, Fungemia and Drug.
His Voriconazole study incorporates themes from Lung, Combination therapy, Terbinafine and Medical record. His Intensive care medicine research is multidisciplinary, incorporating elements of Epidemiology, Adult patients and Disease. His Aspergillosis research includes themes of ARDS, Microbiology, Mucorales, Superinfection and Bronchoalveolar lavage.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Oliver A. Cornely;Johan Maertens;Drew J. Winston;John Perfect.
The New England Journal of Medicine (2007)
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Thomas J Walsh;Hedy Teppler;Gerald R Donowitz;Johan A Maertens.
The New England Journal of Medicine (2004)
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
O.A. Cornely;M. Bassetti;T. Calandra;J. Garbino.
Clinical Microbiology and Infection (2012)
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Ernst-Ruediger Kuse;Ploenchan Chetchotisakd;Clovis Arns da Cunha;Markus Ruhnke.
The Lancet (2007)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A Cornely;Derrick W Crook;Roberto Esposito;André Poirier.
Lancet Infectious Diseases (2012)
Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High–Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
Oliver A. Cornely;Johan Maertens;Mark Bresnik;Ramin Ebrahimi.
Clinical Infectious Diseases (2007)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens;Issam I. Raad;Kieren A. Marr;Thomas F. Patterson.
The Lancet (2016)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann;J. M. Aguado;S. Arikan-Akdagli;D. W. Denning.
Clinical Microbiology and Infection (2018)
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update
J Maertens;O Marchetti;R Herbrecht;O A Cornely.
Bone Marrow Transplantation (2011)
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
O.A. Cornely;S. Arikan-Akdagli;E. Dannaoui;A.H. Groll.
Clinical Microbiology and Infection (2014)
Mycoses
(Impact Factor: 4.931)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Strasbourg
University of Cologne
Canisius-Wilhelmina Ziekenhuis
KU Leuven
KU Leuven
Radboud University Nijmegen
Boston Children's Hospital
University of Genoa
University of Cologne
Statens Serum Institut
Coventry University
Australian National University
University of Cambridge
Stanford University
Indian Institute of Science
Queensland University of Technology
Arizona State University
University of North Carolina at Chapel Hill
University of Florida
Government of the United Kingdom
Baylor College of Medicine
University of Southampton
European Centre for Medium-Range Weather Forecasts
University of Liège
Mayo Clinic
Hannover Medical School